Clinical effect analysis of sacubitril valsartan sodium tablets in the treatment of dilated cardiomyopathy
Objective To observe the clinical effect of sacubitril valsartan sodium tablets in the treatment of dilated cardiomyopathy.Methods A total of 62 patients with dilated cardiomyopathy were divided into a control group(31 cases,conventional medication)and an experimental group(31 cases,conventional medication+sacubitril valsartan sodium tablets)based on two-color ball random grouping method.Patients in both groups were compared in terms of clinical efficacy,incidence of adverse reactions,cardiac function index,plasma N-terminal pro-brain natriuretic peptide,plasma B-type natriuretic peptide,serological index and myocardial protein.Results After treatment,the left ventricular end-diastolic diameter and left ventricular end-systolic diameter in both groups were lower than those before treatment,and the left ventricular ejection fraction was higher than that before treatment(P<0.05).Compared with the control group[(62.55±2.45)mm,(56.51±3.44)mm,(54.31±2.31)%],the left ventricular end-diastolic diameter(55.15±2.42)mm and the left ventricular end-systolic diameter(48.17±3.48)mm were decreased in the experimental group after treatment,and the left ventricular ejection fraction(64.16±2.35)%)increased(P<0.05).After treatment,the plasma N-terminal pro-brain natriuretic peptide and B-type natriuretic peptide in both groups were decreased compared with those before treatment(P<0.05).Compared with the control group[(3354.69±131.49),(408.18±29.83)ng/L],plasma N-terminal pro-brain natriuretic peptide(2926.51±125.54)ng/L,and B-type natriuretic peptide(219.54±29.87)ng/L were significantly decreased in the experimental group after treatment(P<0.05).After treatment,the serum aldosterone,norepinephrine and angiotensin Ⅱ in both groups were decreased compared with those before treatment(P<0.05).Compared with the control group[(248.26±10.41)ng/L,(63.79±3.43)μg/L,(58.03±3.48)ng/L],the serum aldosterone(281.21±10.45)ng/L,norepinephrine(48.45±3.48)μg/L and angiotensin Ⅱ(51.36±3.42)ng/L were significantly decreased in the experimental group after treatment(P<0.05).After treatment,the troponin T and troponin I in both groups were lower than those before treatment(P<0.05).Compared with the control group[(0.41±0.09)and(0.53±0.09)μg/L],troponin T(0.28±0.06)μg/L and troponin I(0.33±0.07)μg/L were significantly decreased in the experimental group after treatment(P<0.05).The total effective rate of 100.00%in the experimental group was higher than 77.42%in the control group(P<0.05).There was little difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril valsartan sodium tablets can effectively enhance the therapeutic effect of patients with dilated cardiomyopathy and has a high safety profile.
万方数据
维普
